HTR3B: Key Enzyme in Neurotransmitter Synthesis (G9177)

Target Name: HTR3B

NCBI ID: G9177

HTR3B

HTR3B: Key Enzyme in Neurotransmitter Synthesis

Human tryptophan hydroxylase (HTR3B), also known as 5-hydroxy-tryptophan hydroxylase (5-HT3-B), is a protein that is expressed in the brain and other organs. It is a key enzyme in the synthesis of neurotransmitters, including serotonin and dopamine, which are responsible for regulating mood, appetite, and other physiological processes.

The HTR3B gene was first identified in 2007 and has since been shown to be involved in the synthesis of serotonin, dopamine, and other neurotransmitters. The encoded protein has a molecular weight of approximately 23 kDa and is expressed in the brain, heart, and other organs.

HTR3B is a member of the G protein-coupled receptor (GPCR) family, which includes over 700 different proteins that are involved in a wide range of physiological processes. GPCR proteins are characterized by a transmembrane domain, a catalytic domain, and an extracellular region that is involved in cell-cell signaling.

The HTR3B protein is involved in the synthesis of several neurotransmitters, including serotonin, dopamine, and melatonin. Serotonin is a well-known neurotransmitter that is involved in mood regulation, appetite, and other physiological processes. Dopamine is another well-known neurotransmitter that is involved in movement, emotion, and motivation. Melatonin is a hormone that is produced by the pineal gland in order to regulate sleep-wake cycles.

HTR3B is also involved in the regulation of other physiological processes, including pain perception, anxiety, and depression. It is thought to be involved in the development of certain mental disorders, such as depression and anxiety, by altering the levels of neurotransmitters in the brain.

Despite its potential role in several important physiological processes, HTR3B is not yet a drug target or biomarker. There is ongoing research into the potential therapeutic uses of HTR3B, including the use of small molecules and other compounds to modulate its activity. For example, some studies have suggested that HTR3B may be a potential target for antidepressants, and that inhibiting its activity may be an effective way to treat depression.

In addition to its potential therapeutic uses, HTR3B is also of interest to researchers because of its unique structure and function. As a GPCR protein, HTR3B is characterized by a transmembrane domain that is involved in cell-cell signaling, as well as a catalytic domain that is involved in the synthesis of neurotransmitters.

The HTR3B gene has also been shown to be involved in the regulation of other genes, including the serotonin transporter (SSRI) gene. This suggests that HTR3B may be involved in the regulation of serotonin levels in the brain, which is thought to play a role in several important physiological processes, including mood regulation, appetite, and sleep.

Overall, HTR3B is a protein that is expressed in the brain and other organs and is involved in the synthesis of several important neurotransmitters. While it is not yet a drug target or biomarker, its unique structure and function make it an attractive target for further research into its role in physiological processes.

Protein Name: 5-hydroxytryptamine Receptor 3B

Functions: This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel

The "HTR3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HTR3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets